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RESUMO 
 
As doenças cardiovasculares (CV) e a osteoporose (OP) estão entre os problemas de saúde 
mais comuns, contribuindo significativamente para o aumento da morbilidade e mortalidade 
da população. Segundo a Organização Mundial de Saúde, as doenças CV são a primeira causa 
de morte no mundo, e a aterosclerose é a principal causa de eventos CV. A OP é a doença 
óssea mais comum, caracterizada pela diminuição da densidade mineral óssea e aumento do 
risco de fraturas de fragilidade e da deterioração estrutural do osso. A incidência destas 
doenças aumenta com a idade e frequentemente coexistem no mesmo doente. Estudos 
epidemiológicos demonstraram claramente que, em indivíduos com patologia CV, o risco de 
fratura osteoporótica é 1,2 a 6,7 vezes maior do que na população geral. Essa relação também 
é observada em doentes com baixa massa óssea que apresentam um risco aumentado de 
eventos CV, calcificação vascular e progressão da aterosclerose.  
A associação entre sistema vascular e esquelético ganhou destaque ao longo dos anos, 
especialmente devido ao paradoxo entre a calcificação vascular e a baixa densidade mineral 
óssea, sustentado por diversos estudos em ratinhos e humanos. 
A calcificação vascular é um marcador do aumento do risco CV e tem sido apontada como um 
possível preditor de eventos CV. Acreditava-se que fosse um processo passivo, inevitável e 
natural do envelhecimento, mas essa deposição de minerais nos vasos mostrou-se mais 
complexa, ocorrendo de maneira organizada, não apenas como uma mera calcificação, mas 
como um processo semelhante à ossificação, com deposição de cristais de hidroxiapatite 
produzidos por células vasculares que têm a capacidade de mimetizar a diferenciação 
osteoblástica, formando uma estrutura semelhante ao osso no sistema vascular. 
Paralelamente, ocorre expressão de várias proteínas associadas ao desenvolvimento normal 
do osso, entre as quais OPG (osteoprotegerina), RANKL (receptor activador do factor nuclear 
ƙB), OPN (osteopontina), colagénio do tipo I e também citocinas pró-inflamatórias implicadas 
na modulação da imunidade adaptativa e consideradas potenciais reguladoras do 
desenvolvimento de lesões ateroscleróticas e calcificações. Apesar do sistema 
RANK/RANKL/OPG e da via Wingless (Wnt) serem característicos do metabolismo ósseo, estes 
foram identificados no desenvolvimento da aterosclerose e podem contribuir para a regulação 
da calcificação vascular. Além disso, o RANKL e a OPG são expressos não apenas por células 
relacionadas com o osso, mas também por muitos componentes do sistema CV, como as 
células endoteliais, as plaquetas e as células musculares lisas presentes nos vasos. Embora haja 
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uma forte associação entre estas proteínas e lesões ateroscleróticas, o mecanismo pelo qual o 
processo de calcificação é regulado ainda é desconhecido. 
A associação entre as doenças CV e a OP é particularmente relevante em doentes com 
doenças inflamatórias crónicas, imunomediadas, como Lúpus Eritematoso Sistémico (LES) e 
Artrite Reumatoide (AR). As doenças reumáticas imunomediadas são distúrbios inflamatórios 
que envolvem vários órgãos e que têm como principais comorbilidades a doença CV e a OP. 
Estes doentes apresentam taxas aumentadas de aterosclerose subclínica, com um risco 5-8 e 
2-3 vezes maior de ocorrência de eventos CV no LES e na AR, respectivamente, e um aumento 
da prevalência de OP em torno de 5-25% no LES e 15-35% na AR. 
 
Este trabalho tem por hipótese que os distúrbios ósseos e vasculares partilham mecanismos 
fisiopatológicos comuns e que existe uma relação entre a progressão de ambas as condições. 
Assim, esta tese teve como objetivo compreender a interação entre os vasos e os ossos no 
contexto de doenças reumáticas inflamatórias através do estudo do efeito da inflamação nos 
tecidos. 
 
Na primeira parte deste estudo avaliámos como, nas doenças reumáticas inflamatórias 
crónicas, especificamente AR e LES, os vasos estão modificados, levando a alterações 
vasculares e à doença CV. Para tal avaliámos as alterações vasculares precoces observadas 
nesses doentes sem eventos CV prévios, através da determinação dos níveis séricos de 
biomarcadores vasculares e do estudo da função endotelial. Após 5 anos, avaliámos a 
incidência de eventos CV na coorte de doentes com AR, e verificámos o contributo de factores 
de risco de doença CV tradicionais assim como de parâmetros relacionados com a AR para a 
ocorrência de eventos CV. Mostrámos que a AR e o LES apresentam padrões distintos nas 
alterações vasculares precoces, mais pronunciadas nos doentes com LES, e que a atividade 
inflamatória foi muito relevante para o aumento dos biomarcadores da ativação endotelial e 
para a disfunção endotelial. Além disso, os doentes com AR têm uma incidência de eventos CV 
muito maior do que a incidência relatada para a população geral Portuguesa, para os quais os 
marcadores inflamatórios e de ativação endotelial contribuem significativamente. 
 
Na coorte de doentes com LES, avaliámos como os biomarcadores do metabolismo ósseo, 
especificamente OPG e RANKL, são afetados pela doença. Constatámos que esses doentes têm 
uma relação sRANKL/OPG aumentada, devido à redução dos níveis de OPG. Além disso, os 
níveis de OPG e sRANKL estão relacionados com os anticorpos específicos do LES, mas não com 
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terapêutica com corticosteroides, sugerindo que o aumento dos estímulos osteoclásticos é 
impulsionado pelos mecanismos próprios da doença. 
 
Finalmente pretendemos compreender o papel da inflamação como denominador comum 
para a interação entre os ossos e os vasos. Para isso, usámos primeiramente um modelo de 
aterosclerose em ratinhos (ApoE-/-) e avaliámos os distúrbios dos ossos e dos vasos e 
verificámos a sua associação com marcadores inflamatórios. Os nossos resultados sugerem 
que a inflamação não é o principal fator para a progressão da aterosclerose e para os 
distúrbios ósseos neste modelo animal, mas que as alterações no transporte lipídico e a dieta 
rica em gordura, associada à idade dos animais, podem desempenhar um papel mais 
expressivo. 
Em segundo lugar, utilizando amostras de osso e de aorta de dadores de órgãos e placas de 
ateroma de doentes com aterosclerose avançada submetidos a endarterectomia carotídea, 
avaliámos o papel da inflamação na relação entre alterações ósseas e a patologia vascular. Os 
nossos resultados sugerem que a relação entre as alterações observadas nos ossos e nos vasos 
em contexto da doença aterosclerótica e da osteoporose podem depender de uma relação 
intrínseca entre os tecidos envolvidos, independentemente da progressão de ambas as 
doenças. 
 
Os resultados obtidos sugerem que a relação entre a aterosclerose e a osteoporose depende 
de uma conexão intrínseca entre os tecidos e que a contribuição dos fatores de risco para a 
progressão da doença, incluindo a inflamação, afeta mais acentuadamente os doentes com 
doenças inflamatórias crónicas imunomediadas. 
 
 
 
 
 
Palavras-chave: Aterosclerose, Osteoporose, Inflamação, Doenças Sistémicas Imunomediadas, 
Doenças Cardiovasculares. 
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ABSTRACT 
 
Cardiovascular diseases (CV) and osteoporosis (OP) are among the most prevalent health 
problems, significantly contributing to increased morbidity and mortality of the population. 
The incidence of these conditions increases with age and they frequently coexist in the same 
patient. Epidemiological studies have demonstrated that patients with CV diseases have an 
increased risk for osteoporotic fractures and that patients with low bone mass have an 
increased risk for CV events. The inflammatory process has been implicated in the 
pathogenesis of both diseases, particularly in patients with immune-mediated rheumatic 
diseases like Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). 
 
In this work we hypothesize that bone and vascular disturbances share common 
pathophysiological mechanisms and that a connection between the progression of both 
conditions exists. Therefore, the aim of this thesis was to understand the interaction between 
vessels and bones in the context of inflammatory rheumatic diseases through the study of the 
effect of inflammation on tissues.  
 
In the first part of this study we evaluated how, in chronic inflammatory rheumatic diseases, 
namely RA and SLE, the vessels are disturbed, leading to vascular alterations and CV disease. 
For that we have assessed the early vascular alterations observed in these patients without 
previous CV events, through the determination of serum levels of vascular biomarkers and the 
study of endothelial function. We have then assessed the incidence of CV events in the RA 
cohort after 5 years and identified the contribution of traditional CV disease risk factors and 
RA-related parameters to CV events. We found that RA and SLE show distinct patterns of early 
vascular changes, more pronounced in SLE patients, and that the inflammatory activity was 
central to the increased endothelial activation biomarkers and to endothelial dysfunction. 
Additionally, patients with RA have a much higher incidence of CV events than the incidence 
reported for the general Portuguese population, for which the inflammatory and endothelial 
activation markers contribute significantly. 
 
In the SLE cohort, we evaluated how bone metabolism biomarkers, specifically OPG 
(osteoprotegerin) and RANKL (receptor activator of nuclear factor-ƙB ligand), are affected by 
the disease. We have found that these patients have an increased sRANKL/OPG ratio, due to 
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reduced OPG levels. Also, both OPG and sRANKL levels were associated with SLE specific 
antibodies, but not with corticosteroids therapy, suggesting that the increased osteoclastic 
stimuli are driven by SLE disease mechanisms.  
 
Finally, we intended to comprehend the role of inflammation as common contributor to the 
interplay between bones and vessels. For that we have first used a mouse model of 
atherosclerosis (ApoE-/-) and evaluated bones and vessels disturbances and verified their 
association with inflammatory markers. Our results suggest that inflammation is not the 
principal driver for atherosclerosis progression and bone disturbances in this animal model, 
but that altered lipid transport and high-fat diet, associated with mice aging, may play a more 
significative role. 
Secondly, using bone and vessel samples from organ donors and atheroma plaques from 
endarterectomized patients with advanced atherosclerosis, we have evaluated the role of 
inflammation in the relationship between bone changes and vascular pathology. Our results 
suggest that the relationship between the changes observed in bones and vessels in the 
context of atherosclerotic disease and osteoporosis, may rely on the intrinsic connection 
between the tissues involved, independently of the progression of both diseases. 
 
Overall, our results suggest that the connection between atherosclerosis and osteoporosis rely 
on an intrinsic connection between the tissues and that the contribution of the risk factors for 
the diseases progression, including inflammation, affect more pronouncedly patients with 
immune-mediated rheumatic diseases.  
 
 
 
 
 
Keywords: Atherosclerosis, Osteoporosis, Inflammation, Immune-mediated Systemic Diseases, 
Cardiovascular Diseases 
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INTRODUCTION 
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Cardiovascular diseases (CV) and osteoporosis (OP) are among the most prevalent health 
problems, significantly contributing to increased morbidity and mortality of the population. 
According to the World Health Organization (WHO), CV diseases are the first cause of death 
worldwide 1, and atherosclerosis is the major cause of CV events 2. OP is the most common 
human bone disease, characterized by decreased bone mineral density (BMD) and increased 
fracture risk due to low bone mass and structural deterioration of bone 3,4. The incidence of 
these conditions increases with age and they frequently coexist in the same patient. 
Epidemiological studies have clearly demonstrated that in patients with CV diseases, the risk 
for osteoporotic fracture is 1.2 to 6.7 times higher than in general population 5. This 
relationship is also observed in patients with low bone mass who have an increased risk for CV 
events, vascular calcification and atherosclerosis progression 6,7. This association is particularly 
relevant in patients with chronic inflammatory, immune-mediated diseases like Systemic Lupus 
Erythematosus (SLE) and Rheumatoid Arthritis (RA) that have increased rates of subclinical 
atherosclerosis 8 with respectively, a 5-8 and 2-3 fold higher risk of CV events 9, and an 
increased prevalence of OP of about 5-25% in SLE 10,11 and 15-35% in RA 12.   
 
 
Vessel inflammation and atherosclerosis 
 
Atherosclerosis is the most common pathologic process that underlies CV diseases 2,13,14. 
Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids, 
inflammatory cells, fibrous elements, cellular waste products and calcium 5,15 in sub-
endothelial regions, leading to narrowing of the arterial lumen (stenosis), which can evolve to 
atheroma plaque formation, plaque rupture and thrombosis. Atheroma plaques and 
progressive stenosis affect mainly large and medium-sized arteries 13,16,17. As a consequence, 
the risk for CV events, like ischemia of the heart, brain or extremities increases 18, particularly 
in the presence of instability of the atherosclerotic plaque 19. It begins with a disruption and 
activation of endothelial cells (ECs) with increased surface adhesion molecules (including 
ICAM-1 (intercellular adhesion molecule 1) and VCAM-1 (vascular cell adhesion molecule 1)) 
leading to augmented vascular permeability that allows the attachment and infiltration of 
lipids and inflammatory cells into the sub-endothelial space. The increased connection of low-
density lipoprotein (LDL) to endothelium and smooth muscle cells (SMCs) raises the 
transcription of the LDL-receptor gene, which is activated by proinflammatory cytokines like 
tumor necrosis factor (TNF) and interleukin (IL-) 1β 20. Oxidative modification of LDL is believed 
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to have an important role in atherogenesis. Even slightly changed LDL may induce the 
expression of adhesion molecules and cytokines by ECs. Increased formation of oxidized LDL in 
the vascular intima might lead to monocyte recruitment 21. The initial sign of atherosclerosis is 
EC dysfunction/activation in response to oxidized lipids in the subendothelium, and expression 
of VCAM-1. This will start both the adhesion of leukocytes and the migration of activated 
platelets into the endothelium. Monocytes and T cells bind to ECs expressing VCAM-1 and 
migrate into the arterial tissue 22. Consequently, there is an increase in the production of 
cytokines and growth factors, lipid accumulation, SMCs proliferation 15 and up-regulation of 
adhesion molecules, with subsequent infiltration and diapedesis of monocytes through the 
arterial intima, leading to the formation of pro-inflammatory foam cells and atherosclerotic 
plaque 16. These inflammatory cells, specifically monocytes, will differentiate into 
macrophages, which will then accumulate lipids forming the foam cells 22 and produce and 
release pro-inflammatory cytokines (e.g. IL-1β and IL-6), creating an inflammatory 
environment and perpetuating this cycle 18. In early lesions, vascular smooth muscle cells 
(VSMCs) proliferate/migrate and form a fibrous cap that encloses the growing lipid core, 
forming a more stabilized plaque. Recruitment, activation and differentiation of monocytes 
into macrophages and dendritic cells (DCs) are induced by the initial vascular activation, which 
is quickly followed by an adaptive immune response and recruitment of T cells 23. Intima 
infiltration by activated T lymphocytes (CD4+, HLA-DR+ e IL-2R+), although in lower number 
than macrophages, has regulatory key functions on atherosclerotic plaque 24. B lymphocytes 
and mast cells are scarce in the intima, but may be seen in the adventitia at sites of 
atherogenesis 25. However, the gradual loss of VSMCs by apoptosis and increase activity of 
matrix-degrading enzymes in the cap, can result in plaque rupture, with subsequent platelet 
aggregation and thrombosis (Figure 1) 26. So, the process is more complex than just a passive 
accumulation of cholesterol in the vessel, as previously thought 24,25. 
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Figure 1 – Representation of atherogenesis and an unstable atherosclerotic plaque 
Plaque formation involves a series of events: (1) EC dysfunction and activation; (2) attachment and 
infiltration of lipid and inflammatory cells into the subendothelial space; (3) Monocytes differentiate 
into macrophages, foam cells formation and release of proinflammatory cytokines; (4) VSMCs 
proliferation and fibrous cap formation, enclosing the growing lipid core; (5) VSMCs apoptosis and 
gradual degradation of the fibrous cap; (6) plaque rupture, with subsequent platelet attachment and 
thrombosis. (Adapted from Wang and Bennett, 2012) 26. EC – Endothelial cell; VSMC – vascular smooth 
muscle cell; ICAM-1 - intracellular adhesion molecule 1; VCAM-1 - vascular cell adhesion molecule 1; 
MCP-1 - monocyte chemotactic protein 1; IL – Interleukin; TNF – Tumor necrosis factor. 
 
 
The highest impact of atherosclerotic disease occurs in adults over 45 years old 15 and 
constitutes one of the top death causes in industrialized nations 27. Atherosclerosis and its 
complications are the leading cause of death and productive loss of life in the Western world. 
This disease progresses silently over decades. There is even evidence of early vascular changes 
during the fetal period 21. Atherosclerosis is a multifactorial disease dependent on 
environment, lifestyle, nutrition and other specific individual characteristics, more than just 
genetics and age.  
Several risk factors for atherosclerosis have been identified. In addition to high plasma 
concentrations of LDL, there are other causes, such as free radicals caused by cigarette 
smoking, hypertension, diabetes mellitus and genetic alterations that lead to endothelial 
dysfunction, which is the initial step of the atherosclerotic process 17,28. This causes the 
development of pores in inter-endothelial junctions. Then, the injured or dysfunctional 
endothelium develops a surface that is conducive to inflammatory cells adhesion, rolling and 
migration to subendothelial region 20. Even though LDL appears to be a significant factor, some 
patients may develop CV diseases without changes in lipid profile 15. 
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Epidemiological studies unequivocally showed an increased vascular risk in individuals with 
high levels of proinflammatory cytokines 29,30 and acute phase reagents 31–34. The elevation of 
inflammatory parameters confers a risk similar or superior to that presented by 
hypercholesterolemia. 
In addition, there is evidence that several infectious agents aggravate CV risk, probably 
exerting their effect through inflammatory mechanisms 35,36. In support of the relevance of 
systemic inflammation are also the results of clinical trials demonstrating a significant 
reduction of CV risk obtained with statins in individuals with elevated inflammatory 
parameters 37. 
The relationship of atherosclerosis with conditions like type 2 diabetes and obesity is also 
partially explained by interactions with inflammatory and immune mechanisms occurring in 
these diseases 38. The adipose tissue is responsible for the secretion of several hormone-like 
molecules called adipokines. These molecules regulate the lipids and carbohydrates 
metabolism and act in the inflammatory response, immune regulation and on angiogenesis, 
inducing low-grade inflammation and having pro-inflammatory and atherogenic effects (e.g. 
leptin, resistin and ghrelin). This regulation is complex and at least one adipokine, adiponectin, 
has been associated with a vascular protective effect, showing an anti-inflammatory and anti-
atherosclerotic action 14,39 in the context of chronic inflammatory/immune-mediated diseases 
(SLE and RA, for example) 40. This possible anti-atherogenic effect was recently corroborated 
by the negative association between serum adiponectin levels and intima-media thickness in a 
large study 41. 
Leptin and adiponectin are the best-studied adipokines in their relationship to atherosclerosis. 
Although there is some divergent data 42, most studies show a pro-atherogenic effect of leptin, 
while adiponectin has been reported to have an athero-protective effect 43,44.  
The key mechanism in atherosclerotic disease is inflammation 45, comprising a complex 
interaction with various cell types and cytokines that relate CV risk factors with immune-
inflammatory activation of the vascular wall 23. Inflammation is present and affects the 
progression of the disease during all phases 27, from fatty streaks and plaque formation to an 
acute episode caused by plaque erosion/rupture and subsequent thrombosis 16,20. As an 
inflammatory disease, endothelial dysfunction and inflammatory lesions are mediated by a 
number of pro-inflammatory cytokines. There is evidence of an increase of IL-1β, IL-6 and TNF 
13,46,47 that contribute to lesion progression 25 and are associated with an aggravation  of CV 
risk, as demonstrated by epidemiological studies 48. 
Innate and adaptive immunity operates in the development of atherosclerosis since immune 
cells and their mediators lead to chronic arterial inflammation. Macrophages, T lymphocytes 
7 
 
and mast cells are responsible for the latent inflammatory response in the vessel wall 22. Pro-
inflammatory cytokines present in atherosclerotic plaques are produced by monocytes and 
macrophages 49. 
Increased serum levels of proinflammatory cytokines favor activation and dysfunction of ECs. 
TNF, IL-1 and INFγ promote the expression of adhesion molecules by ECs, the recruitment and 
activation of inflammatory cells and may be responsible for triggering the cascade of 
inflammation in the arterial wall 50. IL-17, activates several downstream pathways, such as 
induction of adhesion molecules, like ICAM-1. However, IL-17 also downregulates the 
expression of endothelial VCAM-1. IL-17 may vary its effects on CV disease depending on the 
cell type that produces it and the environment where it acts, suggesting that IL-17 could have 
both pro- and anti-atherogenic roles 22,23. Fibrinogen, often elevated in inflammatory diseases, 
by binding to vascular receptors such as ICAM-1, acts as a key link to increase adhesion and 
transendothelial migration of leukocytes 51.  
The pro-inflammatory cytokine IL-1β, produced by monocytes and macrophages, is responsible 
for activation and up-regulation of ECs and leukocyte adhesion molecules, proliferation of 
VSMCs and secretion of other cytokines associated with the progression of atherosclerosis 
and, in some human studies, high expression of IL-1β was found in arteries with 
atherosclerotic lesions 16. IL-1β is implicated in several diseases, such as diabetes and leukemia 
but also in diseases with a strong inflammatory component like inflammatory bowel disease, 
RA 52 and also, atherosclerosis 53. In fact, according to the CANTOS study 54, IL-1β inhibition 
with canakinumab reduces hs-CRP and IL-6 levels, as well as the incidence of myocardial 
infarction, stroke and CV death, without any detectable impact on lipids plasma levels 55,56. Il-
1β often acts together with IL-6, another essential cytokine in the progression of 
atherosclerotic lesions and its rupture, triggering inflammation and expansion of inflammatory 
response in atherosclerosis and other chronic systemic inflammatory diseases. It is secreted 
into the lesions by macrophages, ECs, fibroblasts and adipose tissues. Its actions lead to 
endothelial dysfunction, VSMCs migration and transition of macrophages into foam cells 16. 
The activation of the inflammatory process leads to interaction with other molecules that 
modulate various mechanisms in other tissues, e.g. adipose tissue and blood vessels, 
increasing the plasma levels of inflammatory mediators like TNF and C-reactive protein (CRP), 
among others 57,58. TNF is also involved in the pathogenesis of systemic inflammatory diseases 
and there is evidence of involvement in atherogenesis and vascular inflammation. The main 
producers of this cytokine are macrophages, monocytes, ECs, VSMCs and fibroblasts. It binds 
to its two receptors, TNF receptor I (TNFR1) and TNF receptor II (TNFR2) and this process 
induces the activation of nuclear transcription factor (NF)-kB. Its role in atherosclerotic disease 
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is mediated by an increase in the expression of vascular endothelial adhesion molecules, 
recruitment of macrophages and leaking of microvasculature. Moreover, it regulates nitric 
oxide synthesis and reactive oxygen species formation that cause endothelial dysfunction. In 
fact, some studies reveal that TNF administration leads to an increased expression of ICAM-1, 
VCAM-1 and E-selectin and production of reactive oxygen species 16. Cytokines such as TNF can 
be up-regulated by NF-kB, which is activated under oxidative stress, creating a vicious cycle 
and maintaining a chronic low-grade inflammatory activity in the vessel. 25,59,60. 
Chronic inflammation makes an important contribution to the proliferation of SMCs and 
remodeling of the vascular wall. However, the mechanical stimuli to which the endothelium is 
directly exposed (e.g. bloodstream forces) is another vector of vascular remodeling. In the case 
of endothelial injury, mechanical stimuli are perceived directly by SMCs, inducing profound 
changes in their properties. Middle layer cells and adventitial fibroblasts also have the capacity 
to undergo rapid phenotypic transformations, proliferate and migrate. In response to 
aggressions, SMCs produce extra-cellular matrix, including collagen and elastin, thus 
contributing to neointima and fibrous plaque formation. The progression of lesions, 
potentiated by various injuries to the vessel wall, is characterized by focal necrosis and by a 
repairing fibroproliferative process that reduces the vascular lumen (atheroma plaque), alters 
blood flow and causes chronic tissues ischemia. If there is thrombosis or embolism of the 
plaque there is a sudden interruption of the blood flow that gives rise to an acute ischemic 
event. Thrombosis is triggered by plaque rupture and exposure of thrombogenic material 
leading to platelet aggregation and activation. The most vulnerable plaques predisposed to 
rupture and atherothrombosis also present an intense inflammatory infiltrate 61.  
The endothelium is the main regulator of the vascular wall, responsible for maintaining the 
balance between vasoconstriction and vasodilation, between stimulation and inhibition of 
proliferation and migration of SMCs and between thrombosis and fibrinolysis. Endothelial 
function is compromised in individuals with established atherosclerotic disease 62, but 
alterations in endothelial function are also an early marker of vascular disease, and may 
precede structural changes in the arterial wall 63. The presence of CV risk factors is a strong 
predictor of endothelial dysfunction 64 and subclinical inflammation correlates with endothelial 
changes 65. These changes are potentially reversible with pharmacological therapies (statins, 
cholestyramine, angiotensin converting enzyme inhibitors or hypoglycemic agents) and non-
pharmacological (diet or exercise) 66,67. 
As the plaque develops, deposition of calcium will also occur. This can happen in two ways: 
some authors defend that the increase of inflammatory cytokines will provide a VSMCs 
reaction, which will migrate, proliferate and turn into osteoblasts-like cells and will cause 
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instability and calcification of the atherosclerotic plaque 17. Others believe that this mechanism 
is more like an endochondral bone formation due to chondrocyte-like phenotype expressed by 
VSMCs. This endochondral bone formation consists in the differentiation of a cartilage model, 
which is posteriorly invaded by osteoblasts and replaced by mineralized bone 68. 
 
 
Bone inflammation and osteoporosis  
 
Bone is one of the most dynamic human tissues, as it remains metabolically active throughout 
life and has pleiotropic functions in the organism. It not only protects the internal organs, 
supports the body and assists in its movement, but also functions as a mineral (calcium and 
phosphorus) and fat reservoir and harbors bone marrow, where hematopoiesis occurs 69. 
Bone is composed of three different cell types: osteoclasts (OCs), osteoblasts (OBs) and 
osteocytes. These cells are responsible for the daily bone renewal in a tightly balanced process 
70–72. On the other hand, the organization of bone as a tissue is dependent on complex 
interactions between three main players: type I collagen, hydroxyapatite crystals and cells 72. 
From a structural perspective bone can be classified in hierarchical levels of complexity, all 
affecting its mechanical properties. It must be stiff, slightly flexible and light to make loading 
possible and facilitate movement 72–74. 
Additionally, bone has a unique characteristic that distinguishes it from other tissues: it can 
respond according to the location and extent of the biomechanical loading and microdamage, 
remove the damaged tissue and replace it with new bone 72,75,76. Disequilibrium of this system 
is observed in bone metabolic diseases, such as primary OP, or as consequence of systemic 
inflammatory diseases such as RA 72,77. This will induce bone fragility and eventually low energy 
fractures 78. 
The bone mechanical properties describe the relationship between applied loads or forces 
(designated as stress) and bone deformation. Deformation is referred to as strain and is 
defined as a relative change in size or shape. Normal strains represent elongation or 
shortening while shear strains represent distortion. Therefore, a load-deformation curve or a 
stress-strain curve are often used to define the biomechanical properties of bone 79. 
The load-deformation curve reflects the structural behavior of bone and describes the amount 
of load needed to produce a unit of deformation. The analogous stress-strain curve reflects the 
material behavior of bone tissue and this curve is generated through a mechanically 
standardized (size and shape) test. Load and deformation have a linear relationship until the 
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yield point is reached; at this time the slope of the curve is reduced. Before the yield point the 
material obeys to the Hooke’s law, which states that there is a proportional relationship 
between stress and strain. This linear relationship is translated by the Young’s modulus, or 
bone stiffness, that measures the resistance of the bone to deformation 80,81. The yield point is 
the cross point of transition from an elastic behavior to a plastic one and corresponds to the 
occurrence of the first microfractures in bone tissue. The slope of the elastic region defines 
bone stiffness, while the strain energy, or toughness, is the energy required to initiate failure 
of the structure and is computed as the area under the curve 79,81. 
Bone tissue is composed of two main patterns, cortical and trabecular bone. Cortical bone 
represents 80% of skeletal bone and is dense and compact with low turnover ratio; it 
constitutes the outer part of all bones, providing mechanical strength and protection 82. The 
trabecular bone, also known as cancellous bone, only composes 20% of the whole skeleton 
and is a spongy-like tissue present in the interior of the bone, highly vascularized and is formed 
by a porous network called trabeculae 83. It is light, quickly adaptable to external biological 
stimulus, flexible and capable of absorbing energy 82. Even though representing only 20% of 
bone, its remodeling rate is much higher than cortical bone. 
The bone matrix comprises an organic and an inorganic phase. The organic phase is composed 
mainly by type I collagen, glycoproteins, proteoglycans and bone cells. On the other hand, the 
inorganic part is formed by carbonated hydroxyapatite crystals (Ca10(PO4)6(OH)2) that are 
distributed among the collagen fibers 80,84–86. The composition and organization of the bone 
matrix gives this tissue unique mechanical properties such as stiffness, ductility, tensile 
strength and exceptional lightness 86,87. In vivo, bone is subjected to several different loading 
modes producing tension, compression, shear, bending, torsion and combined loading. In 
bending, a combination of tensile and compressive loads is applied in such a way that causes 
the structure to bend. Bending tests can be produced by three (three-point bending) or four 
(four-point bending) forces and are mostly applied to long bones 88,89. 
The organic component of bone is comprised by type I collagen (90%) and noncollagenous 
proteins. Type I collagen is synthesized by OBs. It self-assembles in fibrils and fibers that are 
deposited in parallel or concentric layers 90–92. There are several non-collagenous proteins on 
bone, such as phosphoproteins, proteoglycans, glycosylated proteins and γ-carboxylated 
proteins. These include osteocalcin (OCL), matrix gla protein (MGP), osteopontin (OPN), bone 
sialoprotein (BSP), alkaline phosphatase (ALP) and osteonectin 79,93. These proteins are all 
involved in the ordered deposition of hydroxyapatite by regulating the amount and size of the 
mineral crystals 91,93–96. 
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The type I collagen is the principal protein of bone, a heterotrimer comprising α1 and α2 
protein chains encoded by the COL1A1 and COL1A2 genes. COL1A1 Sp1 polymorphism is 
associated with osteoporotic fractures and the density of bones 4. 
In clinical practice, products of the collagen processing or breakdown, either for the formation 
or degradation, act as markers of collagen turnover and are used to assess bone remodeling 97. 
Type I collagen propeptides, amino-terminal (P1NP) and carboxy-terminal (P1CP) result from 
post-translational cleavage of the pro-collagen molecule before its organization in fibrils 98. The 
propeptides P1NP and P1CP are two small domains present in the procollagen molecule, which 
after secretion of the molecule into the extracellular space are enzymatically cleaved. Since 
both propeptides are stochiometrically produced from each new collagen molecule, P1NP and 
P1CP are considered quantitative measures of collagen formation 99. Moreover, P1NP serum 
levels correlate with bone formation indices assessed by histomorphometry 100–102. The 
strength of the collagen fibers depends on the formation of covalent cross-links between the 
telopeptides and the adjacent helical domains of collagen molecules. The cross-linked 
telopeptides of type I collagen, amino (NTX) and carboxy-terminal (CTX), are products of the 
collagen cleavage. Both NTX and CTX are products of cathepsin K (CTSK) action and represent 
collagen breakdown 101–104. 
Osteocalcin is exclusively expressed in bone and dentin. It is a calcium-binding protein 
characterized by three gamma-carboxyglutamic acid residues. Due to its interaction with 
hydroxyapatite it is believed that OCL regulates the growth and maturation of bone crystals 105. 
In fact, OCL measurements in serum have proven to be a valuable marker for bone turnover in 
metabolic bone diseases 97. 
The endpoint for matrix mineralization is the deposition of crystals between collagen fibers, a 
process that comprises two phases, an initial formation of apatite crystals within matrix 
vesicles and a subsequent propagation phase within the matrix 106. 
Both collagen and non-collagenous proteins regulate the expansion of crystals, while cells can 
affect their maturation status 106. 
There are three main cell types present in bone: (i) OCs, giant multinucleated cells derived 
from macrophage-monocyte lineage that resorb bone by dissolving the mineral phase and by 
enzymatically degrading extracellular matrix proteins; (ii) OBs, cells of mesenchymal origin 
responsible for bone formation that are able to produce the organic bone matrix and aid in its 
mineralization; (iii) and osteocytes, that are mature OBs that become entrapped in the bone 
matrix and act as mechanosensors, a crucial function in the regulation of bone remodeling 
85,107,108. 
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Bone resorption and formation not only should be quantitatively balanced but must also be 
coupled in time and space. This tight coupling is essential for the repair of microscopic 
damages that result from constant impact 109. Bone remodeling (Figure 2) is a dynamic and 
continuous process that occurs throughout life, in which old bone is replaced by new one 
through the action of OBs, OCs and osteocytes 110,111. These cells have a central role in the 
maintenance of the skeleton mechanical integrity and repair of fractures 111. 
 
 
 
Figure 2 – Representation of bone remodeling 
Osteoclasts (OCs) are derived from hematopoietic stem cells (HSCs) and become activated by RANK-
RANKL binding and M-CSF stimuli, acquiring the ability to resorb bone and release growth factors and 
calcium, allowing mesenchymal stem cells (MSCs) differentiation into osteoblasts (OBs). OBs will replace 
the cavities with new bone, with the production of type I collagen and its subsequent mineralization to 
form the calcified matrix of bone. Osteocytes, terminally differentiated OBs embedded in bone, sense 
mechanical strain and signal to OCs and OBs, thus participate in the remodeling process. (Adapted from 
Weilbaecher K. et al., 2011) 112. M-CSF - macrophage colony stimulating factor; RANK - receptor 
activator of NF-κB; RANKL - RANK ligand. 
 
 
OCs, derived from hematopoietic lineage 109, are the unique bone resorbing cells, formed by 
cytoplasmic, but not nuclear, fusion of mononuclear precursors of the monocyte/macrophage 
lineage of the bone marrow (hematopoietic stem cells - HSCs), peripheral circulation and tissue 
macrophage populations 113–116. Osteoclastogenesis is a complex process that includes many 
stages, such as commitment, differentiation, multinucleation and activation of immature OCs 
117,118. OCs formation, differentiation, function and survival are regulated by a network of 
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signaling pathways and depend on two major factors: macrophage colony stimulating factor 
(M-CSF) and receptor activator of nuclear factor-κB (RANK) ligand (RANKL) 115,119–121. 
M-CSF is an hematopoietic growth factor expressed by OB lineage cells involved in the 
proliferation, differentiation and survival of monocytes, macrophages and bone marrow 
progenitor cell 122,123. M-CSF interacts with CSF1R expressed on OC precursors, which is 
essential for their proliferation and survival and stimulates surface expression of RANK 124,125.  
RANKL is a member of the TNF superfamily. It is expressed by bone marrow stromal cells, OBs, 
osteocytes, chondrocytes and immune system cells and interacts with its receptor RANK, 
expressed at the cell surface of OC precursors to induce OC differentiation 119,126–130. RANK is a 
type I transmembrane receptor protein, member of the TNF receptor superfamily,  expressed 
primarily on the cells of the monocyte/macrophage lineage including OC precursors and DCs 
but also on B and T cells and neutrophils 119,131–133.  
RANKL exists both as soluble and membrane-bound forms 93. The soluble form (sRANKL) 
corresponds to the c-terminal part of membranous RANKL that may be produced either 
directly by the stromal cells or OBs through alternative splicing followed by secretion to the 
extra-cellular medium, or by proteolytic cleavage of membranous RANKL by TNF- α converting 
enzyme (TACE) 110. Membrane-bound RANKL is expressed at the cell surface of OBs, bone 
marrow stromal cells, fibroblasts, mammary epithelial cells and activated immune system cells 
124. Deletion of the RANKL gene in mice resulted in severe osteopetrosis and a complete lack of 
OCs, as a result of an inability of OBs to support osteoclastogenesis 134.  
RANKL also binds to another TNF receptor family member, osteoprotegerin (OPG), which is 
produced by OBs, bone marrow stromal cells, immune system cells 124,135,136 and expressed in 
normal VSMCs and downregulated in calcified VSMCs 137. OPG was first identified in 1997 as 
being a protein that exhibits a protective effect on bone 138, although it is expressed 
ubiquitously and abundantly in many tissues and cell types 139. When bound to RANKL, OPG 
prevents its binding to RANK and thus inhibits the biological activity of RANKL, being the major 
negative regulator of bone resorption 119,140–143. It also exhibits a protective effect against 
calcification in cells by reducing alkaline phosphatase 137. OPG-/- mouse exhibit a decrease in 
total bone density with severe trabecular and cortical bone porosity, thinning of the skull, and 
a high incidence of fractures 144, contrary to OPG overexpression that causes severe 
osteopetrosis in mice 138. 
These studies demonstrated the importance of the RANKL/OPG ratio in OC differentiation and 
on its bone-resorptive function 125. The amount of RANKL and OPG expressed by OBs depend 
on their stage of differentiation: pre-OB cells express high levels of RANKL and relatively low 
levels of OPG, thus stimulating OC differentiation and function. On the other hand, more 
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mature OBs express higher levels of OPG, in comparison to RANKL levels, inhibiting OC 
differentiation and function 145. Hence, the RANKL/OPG ratio in bone microenvironment is the 
main molecular mechanism that determines osteoclastogenesis. 
Together, M-CSF and RANKL are required to induce expression of OC lineage-specific genes, 
including those encoding TRAP, CTSK, calcitonin receptor (CALCR) and αvβ3 integrin, leading to 
the development of mature OCs 113. 
OC precursors differentiate into TRAP+ mononuclear cells after RANKL stimulation. These cells 
fuse with each other and differentiate into multinucleated OCs 146. Cell fusion is one of the 
most distinctive characteristic properties of OCs. The OC also contains a unique and complex 
ruffled membrane, which is the resorptive organelle. Although the origin of this specialized 
membrane was enigmatic for some time, it is now considered to be the most specific marker 
of the OC, since it appears only when the cell is resorbing bone 147–149. Mature OCs express high 
levels of tartrate-resistant acid phosphatase (TRAP), which has been widely used as a 
cytochemical marker of OCs and their precursors 150 and several other genes that regulate their 
resorptive ability, including those encoding the chloride/H+ antiporter channel CLCN7 and CTSK 
115,120. TRAP is a soluble acid resistant phosphatase secreted by the OC that plays a role in bone 
resorption 151. 
Bone resorption is a complex and specific process that occurs in three stages: (i) OC 
attachment to bone matrix and cell polarization, (ii) resorption, and (iii) cessation of 
resorption. The first study about the basic mechanism of bone degradation was performed in 
1985 and established that the resorptive space is a highly acidified microenvironment [183]. 
Bone collagen degradation occurs through the action of a lysosomal enzyme, CTSK, which also 
polarizes to the ruffled membrane upon OC attachment to bone 152. After removal of the 
inorganic bone phase and exposure of the matrix proteins, procathepsin K is activated. CTSK is 
secreted by OCs to degrade several bone matrix proteins, among which are included type I 
collagen and OPN. CTSK degrades type I collagen in its non-collagenous termini (N- and C-
telopeptide regions) and releases crosslinked N- and C-telopeptides (NTX-I and CTX-I), which 
can be detected in urine and serum by immunoassays and are currently used to assess bone 
turnover 153,154. 
OBs are mononuclear, non-terminally differentiated, specialized cells that derive from the 
mesenchymal stem cell (MSC) lineage 109,155 and have the ability to secrete bone matrix where 
hydroxyapatite crystals deposit 145,156,157. OBs, chondrocytes, adipocytes, myoblasts, tendon 
cells and fibroblasts are all derived from MSC. The lineages are determined by specific 
transcription factors 157. The differentiation of a MSC into a functional OB requires the 
presence of three transcription factors, core-binding factor subunit alpha-1 (Cbfa1, also known 
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as runt-related transcription factor 2 - Runx2), osterix (Osx) and Wnt/β-catenin 158.  More than 
a decade ago, Cbfa1 was established as essential for bone formation since mice deficient in 
this transcription factor showed no ossification 159. Cbfa1 is a member of the runt family of 
transcription factors that is expressed by MSCs at the onset of skeletal development and is 
present in OBs throughout their differentiation 160. Osx is another essential transcription factor 
for OB differentiation. Osx transcription is positively controlled by Cbfa1 161. Osx acts by 
forming a complex with NFATc1 (nuclear factor of activated T cell c1) resulting both in the 
activation of the type I collagen promoter 162 and in the induction of Wnt signaling pathway 
and bone formation 163. 
The progressive development of the OB phenotype from a proliferating immature cell to a 
mature OB that is able to synthesize bone proteins is characterized by a sequential expression 
of specific genes that identifies three periods of OB phenotype development: proliferation, 
maturation and extracellular matrix synthesis, and matrix mineralization 164. OB differentiation 
and function, and therefore bone formation, is under the control of bone morphogenic 
proteins (BMPs) and Wnt signaling pathways 107,158. The Wnt signaling pathway regulates 
several aspects of OB activities, including commitment of MSCs, OB progenitor amplification 
and cell death. The first evidence that Wnt/β-catenin signaling plays an important role in bone 
formation came from studies in humans where mutations that inactivate the Wnt co-receptor 
low density lipoprotein receptor-related protein (LRP)5 were shown to cause OP 165. 
In the absence of Wnt proteins, glycogen synthase kinase-3β (GSK-3β) phosphorylates β-
catenin, which is degraded, and the OB signaling cascade is blocked, so the MSCs become 
chondrocytes or adipocytes 166,167. The Wnt/β-catenin pathway is frequently referred to as the 
canonical pathway and it promotes cell fate determination, proliferation and survival through 
the increase of β-catenin levels and alteration of gene expression by the transcription factor 
lymphoid enhancer factor/T cell factor (LEF/TCF) 166,168,169. Activation of this signaling  pathway 
occurs with binding of Wnt to the receptor Frizzled (FZ) and the co-receptors LRP5/6 170–172. 
Some molecules specifically block the Wnt pathway such as secreted Frizzled related proteins 
(sFRPs), Wnt inhibitory factor (WIF), the dickkopf-related protein 1 (DKK1) and sclerostin 
(SOST) 172–175. DKK1 is a soluble inhibitor of Wnt pathway produced by osteocytes and OBs 169. 
It interacts with LRP5/6 and transmembrane proteins kremen1 and 2, leading to the 
internalization of this complex and degradation by the proteasome 176. Its overexpression leads 
to inhibition of OB proliferation and impaired mineralization 173 and its blockade leads to 
increase in bone mass 177–179. Another inhibitor of the Wnt pathway is SOST, a secreted protein 
mainly expressed by osteocytes 180. This protein is secreted in response to mechanical stimuli, 
arresting bone formation, as shown in both animal model and human disease 181–185. Like DKK1, 
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SOST inhibits Wnt/β-catenin pathway by binding to LRP5/6 co-receptor; however, it binds to a 
different region of LRP5/6 and it does not mediate receptor internalization 169,186. SOST 
knockout mice have increased BMD, bone volume, bone formation and bone strength 182 while 
overexpression of SOST leads to osteopenia 180.  
During the post-proliferative phase, which is characterized by high levels of ALP, the 
extracellular matrix progresses to the mineralization phase, in which OBs synthesize several 
proteins associated with the mineralized matrix 187 including BSP 188, OPN and OCL 189. Collagen 
type I, ALP and OCL are specific phenotypic markers of OBs expressed during its differentiation 
119. OCL is expressed only in the post-proliferative phase, showing highest levels during 
mineralization 119,190.  
Besides synthesis and deposition of extracellular matrix proteins OBs are also responsible for 
the synthesis and secretion of molecules responsible for initiate and control OCs 
differentiation 119. OBs have the ability to regulate bone resorption through the expression of 
RANKL, which binds to its receptor, RANK, on the surface of pre-OC cells, inducing their 
differentiation. On the contrary, the soluble decoy receptor OPG, also produced by the OB, is 
able to block RANK/RANKL interaction by binding to RANKL and thus prevent OC 
differentiation and activation 191.  
At the end of the bone formation phase OBs have one of three possible fates: they can be 
embedded in the matrix and differentiate into osteocytes, they can become bone lining cells or 
they can undergo apoptosis 158,192–195. When OBs become entrapped in the bone matrix a 
dramatic shift in both shape and function occurs and the cell becomes an osteocyte.  
Osteocytes are non-proliferative, terminally differentiated cells and constitute the main 
cellular component of mammalian bone, representing more than 95% of bone cells. They 
reside both in mineralized matrix and in newly formed osteoid, locked inside small lacunae. 
Osteocytes have dendritic morphology 126,196,197. Once embedded into the bone matrix, the 
osteocyte ceases its matrix synthetic activity and initiates the function as strain and stress 
sensor 198. Another function of osteocytes within the bone cell network is the ability to deposit 
and resorb bone around the lacuna in which they are housed, thus changing the shape of the 
lacuna. This process is called osteocytic osteolysis and is limited to specific situations 199. 
Osteocyte differentiation is accompanied by progressive reduction of several bone markers 
such as ALP, BSP, OCL, type I collagen and Cbfa1 198,200. Although osteocytes by themselves do 
not resorb or form bone, except in the lacunar area, they signal OBs and OCs to perform their 
functions 201. Osteocytes have been shown to produce RANKL and M-CSF and to support the 
generation of functional resorbing OCs from their progenitors 202,203. These cells also express 
OPG, influenced by β-catenin signaling 204,205. Mechanical pressures and loads are sensed by 
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osteocytes and these cells are able to respond by modulating the expression and secretion of 
many molecules, including Insulin-like growth factor (IGF)-I, IGF-II, OCL 206 and type I collagen 
207. Osteocytes also produce two important inhibitors of OB proliferation and differentiation: 
SOST 180 and DKK1 173,208. 
Bone is continuously remodeled to ensure mineral homeostasis and to maintain the integrity 
and strength of the structure. Bone remodeling occurs at the BMU (basic multicellular unit) 
level and involves several sequential steps, beginning with OC formation, OC-mediated bone 
resorption, a reversal period where the matrix will be prepared for the next phase and a long 
period of bone matrix formation mediated by OBs, followed by mineralization of the matrix 
192,209,210. 
The correct balance between bone deposition and resorption is crucial for the proper 
maintenance of bone mass and loss of this coupling mechanism is the starting point for several 
skeletal pathologies 77,211, such as OP, characterized by low BMD and increased resorption, or 
osteopetrosis characterized by excess bone formation that leads to high BMD 212. 
OP is a skeletal condition characterized by an imbalance in bone turnover with loss of bone 
mass and deterioration of bone microarchitecture resulting in decreased BMD and increased 
bone fragility. OP is a major risk for fragility fractures, causing substantial morbidity mainly 
amongst the elderly 4,108,213–215. 
About 40% of postmenopausal Caucasian women are affected by OP and in the context of an 
aging population, this number is expected to increase significantly over the years. The patient 
with OP has an increased lifetime fracture risk, which most commonly occur in the spine, hip 
or wrist 126.  
OP and consequent fractures are a serious public health problem and a significant cause of 
morbidity and mortality with a tendency to become worse due to the increase of life 
expectancy. Accordingly, 30-50% of women and 15-30% of men will suffer a fracture related to 
OP in their lifetime and, by 2050, the worldwide incidence of hip fractures will increase by 
310% in men and 240% in women. The risk of death can be amplified by 20% to 24% during the 
first year after a hip fracture and the majority of those who survive can become bedridden. 
This disease is more common in the European countries but its prevalence is increasing in 
developing countries in Asia and Latin America 119,216. Low BMD is a major risk factor for 
fractures. BMD determination is possible by performing a dual x-ray absorptiometry (DXA). The 
result is evaluated in T-score values, which is the number of standard deviations observed in 
the comparison between individual measured BMD and the mean BMD of a young population 
(bone mass peak). According to the WHO, OP is diagnosed if T-score < -2.5, ostepenia if T-score 
≥ -2.5 and ≤ -1.0, and normal if T-score > -1.0 217. 
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Primary OP is the most common type of OP, mainly defined as an age-related condition, 
characterized by bone mass loss increasing with age, leading to weakening of bones and 
fractures 218,219. It is also associated with menopause, mainly due to estrogen deficiency that 
causes an impairment in bone turnover cycle, causing this disease to be more frequent in 
women that in men 219,220. 
Secondary OP, on the other hand, has a direct identifiable cause. It is essentially associated 
with endocrine, metabolic or inflammatory diseases such as RA 221, SLE 222 and ankylosing 
spondylitis 223, or medications that cause bone metabolism imbalance 224. Its complexity is due 
to its heterogeneous character, attributed to various endocrine, metabolic, and mechanical 
factors along with the usual risk factors such as age, menopause and certain lifestyle behaviors 
108,215. 
A relevant component of the fracture risk is hereditarily related and previous studies have 
shown that the value of BMD is 50% to 85% genetically determined 4.  
Age-related bone loss affects both women and men. Significant trabecular loss begins in the 
early thirties in both genders but after menopause women experience acceleration in bone 
loss due to the rapid decline in estrogen after menopause 108. In men, age-related changes in 
the levels of sex steroids, including both androgen and estrogen, also contribute to the 
pathogenesis of OP 225. The variations in serum markers of bone turnover have been studied in 
a group of postmenopausal women showing that menopause induces a 79-97% increase in 
bone resorption marker levels and 37-52% increase in bone formation 226. In early menopause, 
the acute phase of estrogen deficiency, the up-regulation of RANKL on bone-marrow stromal 
cells is associated with increased bone resorption 227,228. In addition, estrogens also stimulate 
the expression of OPG in mouse OBs and stromal cells 229 and suppress the expression of TNF, 
IL-1 and IL-6 in monocytes, OBs and stromal cells 230. Therefore, estrogens play a protective 
role in bone loss by modulation of the RANKL/OPG ratio and inhibition of pro-inflammatory 
cytokines secretion. 
Rising molecular evidence suggests that inflammatory conditions with release of inflammatory 
cytokines like IL-1, IL-6, IL-17 and TNF can modulate bone by promoting (in the case of IL-1, IL-
6, IL-17 and TNF) or inhibiting (IL-12, IL-33 and also the IL-6 which has this double function) 
osteoclastogenesis 231 as well as leading to alternative pathways within bone remodeling 
60,231,232. The term osteoimmunology was used for the first time in 2000 233 to describe the 
interaction of cells from the immune and skeletal systems. This connection between bone and 
immune systems is not surprising, since precursors of immune cells reside in bone marrow, 
thus in the same environment as differentiated bone cells. Moreover, OCs are of 
hematopoietic origin. In addition, a new concept is emerging in which bone exerts a quality 
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control on immune responses by controlling the availability of HSCs 234. Immune and skeletal 
systems have several regulatory factors in common, such as cytokines, transcription factors 
and receptors. Consequently, these two systems interact with each other, both in physiological 
and pathological conditions. Furthermore, as we age there is accumulation in the bone 
marrow of memory T cells, which express RANKL on their surface. It is believed that these cells 
might influence bone turnover and be responsible for some of the changes that occur in the 
skeleton with aging 235. 
 
 
Atherosclerosis and Osteoporosis interplay 
 
The association between vascular and skeletal system has gained prominence over the years, 
especially the paradox between vascular calcification and low bone density, supported by 
several studies in mice and humans.  
Vascular calcification is a well-accepted marker of increased CV risk 236 and has been pointed as 
a possible predictor of CV events 5,237. It is shown to be an active, cell-regulated process 
characterized by an ectopic mineral deposition in blood vessels, predominantly aortas. This 
mineralization can occur either in the tunica intima, associated with atherosclerosis (related 
with lipid accumulation and inflammation with focal plaque calcification) or in the tunica 
media of the vessel, a more generalized stiffening, known as arteriosclerosis or Monckeberg’s 
medial calcified sclerosis (associated mostly with ageing, OP and other conditions like 
hypertension or diabetes mellitus) 68,238. It was thought to be a passive, inevitable, natural 
process of ageing, but this deposition of minerals in the vessels was shown to be more 
complex and occurring in an organized manner. It is not a mere calcification, but an 
ossification-like process with deposition of mineral hydroxyapatite produced by calcifying 
vascular cells that have the ability to recapitulate the osteoblastic differentiation, leading to a 
bone-like structure in the vascular system 239. This phenomenon is paralleled by the expression 
of several proteins implicated in normal bone development. Among these proteins believed to 
mediate arterial wall calcification stand OPG, RANKL, OPN, type I collagen and also pro-
inflammatory cytokines 240, implicated in modulating adaptive immunity and considered as 
potential regulators of atherosclerotic lesions development and calcification. Despite 
RANK/RANKL/OPG system and the Wnt pathway being characteristic of bone metabolism, they 
have been identified in the development of atherosclerosis and could be a contributing 
pathway in regulation of vascular calcification 136. Furthermore, both RANKL and OPG are 
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known to be expressed not only by bone-related cells but also by many components of the CV 
system, such as ECs, platelets, and VSMCs 236,241,242. 
Previous studies have shown that increased OPG serum levels and its expression are 
associated with carotid atherosclerosis, myocardial infarction and with low BMD in 
postmenopausal women 243,244. OPG serum levels are also related to atherosclerotic plaque 
growth, vascular calcification, increased risk of CV disease, peripheral arterial disease and CV 
mortality 245–248. Animal model studies have demonstrated that OPG-/- mice, on top of being 
osteoporotic, have also shown an unexpected increase in vascular calcification 240, raising the 
hypothesis that OPG is a key regulator, not only of OP but also of vascular calcification 5,249. In 
humans this association was also demonstrated in several epidemiological studies 250,251. 
Clinical data have shown increased levels of OPG in association with endothelial dysfunction, 
vascular calcification, CV events and increased mortality 248. RANK and RANKL expression by 
peripheral blood leukocytes is increased in patients with unstable angina, as well as monocytes 
/ macrophages in thrombus removed from acute myocardial infarction (AMI) patients and on 
atheroma plaques in animal models, pointing to a likely role of RANK/RANKL on plaque 
instability 252. In accordance, in RA patients, OPG levels correlate with coronary calcium score 
253. Although there is a strong association between these proteins and atherosclerotic lesions, 
the mechanism by which the calcification process is regulated is still unknown 248,254,255. 
There are evidences linking atherosclerosis and CV mortality with low bone mass 9,256. It is 
probable that OP and CV disease share common risk factors 5,256 as well as molecular and 
pathophysiological mechanisms 19,68,251,257. Thus, there are possibly common underlying 
mechanisms shared by both conditions that are not yet fully understood. 
 
 
Vessels, bones and systemic immune mediated diseases 
 
Immune mediated rheumatic diseases, which include conditions such as RA and SLE, are 
inflammatory disorders that can involve multiple organs 258,259 and have as major comorbidities 
premature CV disease and OP, due both to underlying disease and chronic exposure to 
glucocorticoids 258–260. 
Whereas the CV manifestations of immune-mediated disease can be mild and clinically silent, 
they can also increase morbidity and mortality substantially. Patients with systemic immune-
mediated conditions often develop atherosclerosis, contributing to a higher mortality than in 
the general population, which is partially explained by an increase in the macrovasculature 
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endothelial damage, related to the persistent inflammatory response and associated with the 
presence of autoantibodies, immune complexes, and monocytes activation, although the 
precise etiology of endothelial damage initiation in an inflammatory context is still an enigma. 
Different components that are characteristic to the immunopathology of immune-mediated 
rheumatic diseases could be involved in the EC activation, increased permeability, functional 
alteration, and vascular injury 258,261.  
Rheumatic conditions are associated with both local (periarticular) and generalized OP. Local 
bone loss is mainly due to the production of cytokines in synovial tissue. The systemic 
inflammatory response may affect the skeleton. In addition, therapy with cytotoxic drugs and 
glucocorticoids may further impair bone cell function 260, either through a direct effect on bone 
cells (upregulation of RANKL expression in OBs and downregulation of OPG in OCs, increasing 
osteoclastogenesis) or indirectly through its effects on muscle and calcium homeostasis 262.  
 
 
Rheumatoid arthritis bones and vessels 
 
RA is a chronic, systemic, immune mediated inflammatory disease that mainly affects the 
synovium of multiple joints, leading to the progressive destruction of cartilage and bone. This 
disease is characterized by pain, swelling and destruction of the synovial joints causing 
functional impairment and a significant increase of both morbidity and mortality 263,264. 
Epidemiological studies have shown that RA affects about 1% of the world population and 75% 
of RA patients are women 265–269. In Portugal, it has been reported that the prevalence of RA is 
0.7% (95% CI 0.5%-0.9%) and it is also more frequent in women than in men 270,271. Its 
incidence is highest among those aged between 30 and 50 years and, due to its chronic nature, 
the prevalence increases with age, as well as co-morbidities 266,268. 
The predominant symptoms of RA are symmetrical pain, stiffness and swelling of peripheral 
joints. The clinical course of the disease is variable, ranging from mild to severe and highly 
destructive arthritis. The analysis of the clinical course and of laboratory and radiologic 
parameters have defined prognostic factors related to progressive joint destruction, such as 
the presence of autoantibodies like rheumatoid factor (RF) and anti-citrullinated protein 
antibodies (ACPA) 272–275. In some patients these markers emerge years before the onset of the 
disease and probably contribute to its development and chronicity 276–279. For classification 
purposes, mainly related to research, patients are classified as having RA based on the 2010 
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American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) RA 
classification criteria 280. 
Evaluation of disease activity must be performed periodically. The disease activity score 28 
joints (DAS28) is a frequent outcome measure used in clinical trials and is also used in 
therapeutic decisions. DAS28 is based on the count of tender and swollen joints (twenty-eight 
tender and swollen joints scores including: shoulders, elbows, wrists, metacarpophalangeal 
joints, proximal interphalangeal joints and knees), inflammatory activity (erythrocyte 
sedimentation rate, ESR or CRP) and the subjective evaluation of the global impact of the 
disease as measured by a visual analogue scale by the patient 281,282.  
As a result of inflammation and structural damage there is a progressive decrease in functional 
capacity. The functional capacity measured by the Health Assessment Questionnaire Disability 
Index (HAQ-DI) is predictive of absenteeism, economic losses, early retirement and increased 
mortality 283. Life expectancy is decreased in RA 284,285. The causes of death of these patients 
are similar to those observed in the general population, but deaths occur 5-15 years earlier 
than would be expected in a population of the same sex and age but without RA 284.  
Two of the most relevant RA comorbidities are OP and CV diseases. Indeed, RA patients have 
an increased risk of vertebral fractures, which is independent of BMD and corticosteroid use 
286,287. In addition, a high hip fracture risk was also noted in RA patients not exposed to 
corticosteroids 287. Thus, RA itself seems to predispose to fractures as it is translated in the 
fracture risk assessment tool (FRAX®) 288. On the other hand, CV diseases are the leading cause 
of death of RA patients. CV diseases account for about 40-50% of deaths, a value that has 
remained stable over the past few decades. Contrary to what is observed in the general 
population, deaths from CV disease remained unchanged in RA patients 264 and this reality 
contributes to an increasing mortality gap between this disease and the rest of the population 
289. In addition, CV events occur about a decade earlier in RA 290, suggesting that this disease, as 
in diabetes mellitus, is an independent risk factor for premature atherosclerosis 291,292. RF-
positive but not RF-negative RA patients are at increased risk of CV events following exposure 
to glucocorticoids 293. 
RA is a complex multifactorial disease with unknown etiopathogenesis. In genetically 
susceptible individuals, specific environmental factors such as smoking habits, trauma or 
infection can activate potentially pathogenic immune pathways, contribute to disease 
development and its perpetuation, leading to chronic inflammation, joint destruction and 
systemic manifestations 265. Among environmental factors, the potential contribution of 
smoking is highlighted. Tobacco predisposes to the transformation of arginine into citrulline 
and this post-translational modification can make several peptides more immunogenic and 
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contribute to the production of ACPA 294. Other environmental stimuli, such as periodontal 
infection by Porphyromonas gingivalis, may interact with genes and trigger an autoimmune 
process 295. In addition to ACPA and RF IgM (Immunoglobulin M), the production of other 
autoantibodies is documented, supporting the importance of B cells in the pathogenesis of RA. 
The signs and symptoms of RA result from synovitis, the inflammation of the synovial 
membrane within joints. A complex network of cells and cytokines are involved in the 
pathogenesis of RA, particularly in the recruitment, activation and effector functions of 
immune cells. The synovial layers become vascularized and infiltrated with macrophages and 
fibroblasts in addition to an influx of B and T lymphocytes, plasma cells, mast cells, DCs and 
neutrophils 268,296.  
In rheumatoid joints, it is well known that the imbalance between pro- and anti-inflammatory 
cytokine activities contributes to autoimmunity, chronic inflammation and therefore joint 
damage 297–299. TNF 300,301, IL-1β 302,303 and IL-6 304,305 are among the most important mediators 
of RA pathogenesis. T lymphocytes and other immune system cells produce pro-inflammatory 
cytokines such as TNF, IL-1β, IL-6 and IL-17A that enhance osteoclastogenesis and activate OCs 
265,306. Cytokines, such as TNF and IL-17, released from activated T lymphocytes, can target 
bone lining cells and fibroblasts and increase RANKL production, promoting OC activity 298,307. 
Synovial T lymphocytes from RA patients produce low amounts of IFNγ but secrete TNF that 
induces RANKL expression in synovial fibroblasts. Moreover, RANKL is also expressed by 
activated T lymphocytes, of which Th17 are a major source 306,308,309. IL-6 induces OC 
differentiation by promoting RANKL expression 310. Blockade of IL-6 receptor reduced OC 
differentiation and bone resorption in monocyte cultures stimulated with RANKL 311. IL-1β is a 
stimulator of TNF receptor-associated factor (TRAF)6 expression in the OC, thereby 
potentiating RANKL-RANK signaling cascade 312. IL-1β can also indirectly facilitate 
osteoclastogenesis by acting on the OB inducing RANKL expression 313.  
There are some similarities between RA and CV disease regarding the chronic inflammatory 
processes. The concentrations of CRP, IL-6 and TNF are elevated, and the cellular recruitment 
and activation patterns are alike. The pro-inflammatory molecules exert deleterious effects on 
the vascular endothelium, which subsequently reduces the synthesis of nitric oxide and 
promotes endothelial dysfunction 314,315, which can occur in both large and small vessels of the 
microvasculature, independently of disease activity or duration 316,317. Also, these pro-
inflammatory molecules induce alterations of further potential CV risk factors such as 
dyslipidemia, insulin resistance and oxidative stress 314. TNF also cleaves vascular endothelial 
(VE)-cadherin 318, an endothelium specific adhesion molecule important in maintaining 
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endothelial tight junctions, whose cleavage could result in increased permeability, interstitial 
edema, and hemorrhage 316. 
In vitro, IL-6 and TNF upregulated oxidized LDL uptake, transforming macrophages into foam 
cells, a process significantly augmented by the serum of RA patients 319. These processes were 
attenuated with inhibition of IL-6 or TNF, supporting the beneficial effect of these therapies on 
the reduction of atherosclerosis risk 319. 
An increase in the carotid intima-media thickness (cIMT), an indicator of subclinical 
atherosclerosis, have been described since early RA 320,321. Nevertheless, RA has also been 
associated with CV disease, despite of cIMT increase, in association with maladaptive outward 
carotid arterial remodeling 2,322. 
The inflammatory environment that occurs in RA induces bone remodeling disturbances, 
contributing not only to bone erosions but also to the development of secondary OP. As in 
physiological conditions, RANK/RANKL/OPG system is a major player in bone resorption in RA 
121,323,324. On the other hand, TNF produced by inflammatory cells induces the up regulation of 
sFRP and DKK proteins inhibiting the Wnt signaling pathway and compromising OB function 
and matrix mineralization 325,326. The sequence and quantity of bone formation is controlled 
both by the temporal regulation and the level of expression of DKK1 173. TNF was identified as 
the key inducer of DKK1 both in animal models and in human RA 325. Indeed, both in vitro and 
in vivo, TNF increases DKK1 expression, blocking OB differentiation, and inhibition of DKK1 not 
only rescued OB formation but also neutralizes TNF-mediated SOST expression in fully 
differentiated OBs 327. TNF increased the expression of inhibitors of the Wnt signaling  pathway 
such as DKK1 and SOST and could precipitate a destructive combination of low bone formation 
and high bone resorption 328. Thus, OB differentiation and function are also abnormal in this 
disease, leading to the uncoupling of bone formation and bone resorption. 
 
 
Systemic lupus erythematosus bones and vessels 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multi-
organ involvement and by the production of autoantibodies directed against a variety of 
nuclear and cytoplasmic antigens 329, and by an anomalous activation of the interferon 
pathway. SLE predominantly affects women of childbearing age, with a peak incidence in the 
3rd decade of life, and 3/4 of the cases are diagnosed between 16 and 49 years of age 330. 
There are large variations in the prevalence and natural history of SLE depending on the 
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geographical areas and ethnic groups studied 331–334. These differences may be due to the 
genetic diversity of the populations concerned, but also to environmental and socio-economic 
factors. In Portugal, it has been reported that the prevalence of SLE is 0.1% (95% CI 0.1%-0.2%) 
and it is more frequent in women than in men 271.  
The great diversity of phenotypic manifestations and the evolution by outbreaks, in which 
periods of exacerbation intersect with periods of remission, are characteristic of this disease. 
Some antibodies are relevant to diagnosis, whereas others are associated with prognostic 
features or disease activity status 335,336. Antibodies against double-stranded DNA (anti-dsDNA) 
and Smith antigen (anti-Sm) are considered very specific for SLE diagnosis, and both are part of 
the immunologic classification criteria for this disease 337. Furthermore, high levels of anti-
dsDNA are associated with higher disease activity in SLE 338,339. The severity of the disease is 
determined by the intensity of the inflammatory response. Persistent inflammation, not 
effectively controlled, leads to irreversible damage that accumulates over the course of the 
disease's progression. 
The evaluation of inflammatory activity and irreversible damage are features that should be 
part of the regular monitoring of these patients 340, and there are several instruments available 
for this purpose. Among the valid, reproducible and sensitive indexes for measuring lupus 
activity 341, the most used are systemic lupus erythematosus disease activity index (SLEDAI), for 
its ease of use 342 and British Isles Lupus Assessment Group (BILAG) for being more informative 
343. SLEDAI is a global index developed, validated and introduced in the clinic in 1985 and 
accounts for the presence of clinical and laboratory manifestations of lupus activity in the 
previous 10 days 342. In 2002 a revised and validated version was introduced, SLEDAI-2K 344. The 
score obtained by this instrument can vary between 0 - 105 and the disease is considered 
active if the result is ≥4 345. To evaluate the damage, a single device, the Systemic Lupus 
International Collaborating Clinics / ACR Damage Index (SLICC-DI), is available 346. This index 
quantifies permanent and irreversible lesions accumulated since diagnosis, regardless of 
whether they result from inflammatory activity, treatment, co-morbidity or a combination of 
these factors. The SLICC-DI score is always increasing and a higher score reflects a poor quality 
of life 347 and a higher risk of death 348,349. Several predictors of damage have been identified, 
including advanced age, some clinical and laboratory characteristics, chronic steroids, the 
presence of co-morbidities and the existence of previous damage are predictive of greater 
damage in the future 350–352. 
Among the various rheumatic diseases that contribute to a decrease in life expectancy, SLE is 
the one in which the adjusted mortality rate is highest, 2 to 5 times higher than expected for 
the age group and for sex 284,353,354. It is among the younger women with recent illness that the 
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highest mortality rate is found 353. CV disease stands out among the causes of death. The 
contribution of CV pathology to late peak mortality remains constant 354–356. Despite the overall 
increase in the life expectancy of SLE patients, CV mortality has remained unchanged over 
years 357. On the basis of excess deaths from this cause is accelerated atherosclerosis and 
thrombotic phenomena 358. Non-fatal CV events are also increased in SLE, with a prevalence 
ranging from 1.8% to 27%, depending on the duration of the disease 359. SLE patients present 
not only an increased risk of fatal and non-fatal CV events but also of subclinical 
atherosclerosis and female gender and premenopausal status do not provide protection 
against atherosclerotic disease. The prevalence of carotid atherosclerotic plaques ranged from 
17% to 32% in patients without previous CV events 360,361.  
SLE patients also have a high morbidity related to bone loss and associated increased fracture 
risk 362–364. Disease flares and cumulative organ damage are associated with bone loss 364. OP 
was found in 10-68% 364 and osteopenia in 25-75% of SLE patients 363,364. Multiple studies have 
demonstrated decreased BMD levels in SLE patients, both at diagnosis and at severe disease 
362,364,365, as well as an increased fracture risk in both men and women 362. However, BMD does 
not necessarily correlate with fracture risk, as 4-30% may develop fragility fractures despite 
normal BMD 364. Risk factors contributing to bone loss in SLE include inflammation, premature 
menopause, physical inactivity, sun avoidance (with the consequent decrease in vitamin D 
levels) and treatment with corticosteroids 365,366. Additionally, patients with SLE share inherent 
OP risk factors with healthy age-matched counterparts, including sex, postmenopausal status, 
age, family history, lifestyle, and low body mass index (BMI) 364,365. 
The etiology of SLE is multifactorial, influenced by genetics, systemic inflammation, serological, 
metabolic, and hormonal factors, lifestyle choices and changes in body composition 363. The 
cause of SLE remains unknown, but it is generally accepted that lupus results from an 
interaction between genetic and environmental factors, leading to complex changes in the 
innate and adaptive immune system. 
Epigenetic alterations, dependent on external stimuli, are fundamental for the regulation of 
gene expression and establish a bridge between genetic and environmental factors 367. 
In SLE, oligoclonal expansion of T lymphocytes, defects in signaling and altered production of 
various cytokines (↓IL-2, ↑INF-α, ↑IL-6, ↑IL-10, ↓TGF-ß) were documented 329,368. 
Additionally, hyper-reactive B lymphocytes play a key pathogenic role through the production 
of numerous antibodies against nuclear antigens, but also to the cytoplasm and the cell 
surface. However, the role of B cells in SLE goes beyond the production of autoantibodies, and 
it is possible to induce lupus in animal models incapable of producing immunoglobulins, 
provided autoimmune B cells were present 369. 
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Elevated levels of IL-6 have been reported to abrogate DNA methylation in B cells, promoting 
the activation and expansion of autoreactive B cells in SLE patients 329. It has also been 
described that IL-17 increases the survival and proliferation of B cells and their transformation 
into antibody-secreting cells 329. 
The pathological features characteristic of lupus includes the deposition of immunocomplexes, 
inflammation and vascular injury. The autoantibodies are responsible for the formation of 
antibody-antigen complexes that mediate the inflammatory process leading to dysfunction 
and injury of various organs. The deposition of immune complexes in tissues leads to 
complement activation, increased production of type I interferon and other cytokines 
fundamental to the activation of T and B lymphocytes. In SLE patients not only there is an 
increased production of immunocomplexes, as its removal is slower 370. 
 The pathologic vascular changes in SLE are characterized first by immune complex deposition, 
subsequent complement activation, swelling, dystrophy and desquamation of ECs, plasmatic 
impregnation of the walls, fibrinoid necrosis, and infiltrative-proliferative cellular reaction with 
small vessel luminal thrombosis followed by the development of sclerosis and premature 
atherosclerosis. With chronicity, all these pathologic changes result in marked atherosclerosis, 
even in young individuals 371.  
Also, SLE patients have an altered lipid profile, influenced by several factors including elevated 
levels of the inflammatory cytokines IL-6 and TNF, with increased very-low-density lipoprotein 
(VLDL) and triglycerides but reduced high-density lipoprotein (HDL), promoting the oxidation 
of LDL and the development of atherosclerosis 372. 
SLE patients have a reduced number 373 or an impaired function 374 of endothelial progenitor 
cells (EPCs), which play a role in endothelial repair and angiogenesis, independently of the 
presence of subclinical atherosclerosis 373. Metabolic syndrome, very frequent in these patients 
and strongly related to inflammation, was reported to contribute to the reduction of 
circulating EPCs and increased arterial stiffness 375. 
The pathophysiology of OP in patients with SLE is likely a combination of several factors, 
including traditional OP risk factors, inflammation, metabolic factors (such as vitamin D 
deficiency), and corticosteroids therapy 376,377.  
Increased cytokine levels (e.g. TNF, IL-1β and RANKL) in bone tissue due to inflammation 
influence differentiation and activity of OBs, osteocytes and OCs, leading to disproportionate 
remodeling by increased bone resorption with reduced formation and thus net bone loss 
366,378. 
Glucocorticoids, extensively used for the treatment of SLE disease flares and complications, 
lead to significant bone loss through inhibition of the differentiation of OBs, impair the 
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production of some anti-resorptive cytokines (e.g. OPG) and increase bone resorptive activity 
379. Systemic use of glucocorticoids increases the risk of fracture, either due to decreased BMD, 
changes in bone structure or a combination of these 378,380. 
 
 
 
 
Animal models of atherosclerosis 
 
Experimental animal models are a valuable tool for providing information on etiology, 
pathophysiology, and complications of a disease and on the efficacy and mechanism of action 
of various drugs and compounds used in treatment 381,382. An animal model is easily 
manageable, as compounding effects of dietary and environmental factors can be controlled. 
Blood vessels and cardiac tissue samples can be taken for detailed experimental and 
biomolecular examination 381. The first evidence that experimental atherosclerosis could be 
induced in animals came into view at the beginning of the 20th century by Alexander 
Ignatowski; since then, numerous animal models have been used for understanding the 
mechanisms involved in both induction and regression of atherosclerotic lesions 381,383. 
Despite its limitations, the mouse remains the favored species for atherosclerosis 
investigation. The two most frequently used models of mouse atherosclerosis are the ApoE−/− 
model (the first mouse gene successfully deleted for atherosclerosis research in 1992 and still 
the most widely used) and the LDLR−/− model 382–384. 
The ApoE knockout mice is a very well established model to study atherosclerosis progression. 
The loss of the gene encoding apolipoprotein E (ApoE), a glycoprotein synthesized mainly in 
the liver and brain that serves as a structural component of VLDL particles, loses their function 
as a ligand for LDL-receptors, predisposing mice to develop atherosclerotic lesions resembling 
those seen in humans 385. 
ApoE-deficient mice are generated by targeting and inactivating the apoE gene, which is 
essential for the transport and metabolism of lipids, leading to lipid accumulation and 
atherosclerotic plaque formation. 
These ApoE knockout (ApoE-/-) mice tend to develop spontaneously and in a short time 386 a full 
range of atherosclerotic lesions distributed throughout the arterial tree, with progression from 
fatty streaks to fibrous plaques 387,388. Although mice do not experience plaque rupture, 
contrary to humans where this is a very common complication of atherosclerosis, they are 
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hypercholesterolemic due to probable delayed clearance of large atherogenic particles from 
the circulation. Female ApoE-/-mice develop atherosclerotic lesions more rapidly 389 and with 
higher mean lesion area 390 than their male counterparts.  
Because this pathology can be exacerbated with a diet rich in fat and cholesterol, with 
appearance of fatty streaks in the proximal aorta at 3 months of age 387, this model is adequate 
to study atherosclerosis progression 388. 
IL-1β exerts an atherogenic action in this animal model by enhancing the expression of VCAM-
1 and MCP-1 in the aorta, which possibly increases the recruitment of 
monocytes/macrophages to the intima 391. Additionally, it has been reported that ApoE-/- mice 
suffer a decrease on bone mass when animals get older 392, but also when they are fed with a 
high fat diet 393,394, possibly by blocking the differentiation of OB progenitor cells 395. 
Interestingly, this process has been suggested as being associated to changes in inflammatory 
cytokines 394 but also to changes in genes associated with both bone resorption and formation 
396. Nevertheless, reduced bone mass has also been observed in C57BL/6 mice 395 and other 
animals 397–399 given a high-fat diet. 
There are, however, some studies that have reported that ApoE−/− mice are characterized by 
high bone mass due to an increased bone formation rate 400,401. Nevertheless, Bartelt et al. 400 
have shown that high-fat diet induced a reduction of bone mass in ApoE−/− mice but not in the 
wildtype. 
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Several epidemiological studies have shown that individuals with CV disease have a higher risk 
of fragility fractures. On the other hand, individuals with low BMD have more CV events and 
deaths. These two diseases, often present in the same individual, are responsible for high rates 
of morbidity and mortality and share common risk factors. Also, the inflammatory process has 
been implicated in the pathogenesis of both diseases, particularly in patients with immune-
mediated rheumatic diseases. We thus hypothesize that bone and vascular disturbances share 
common pathophysiological mechanisms and that a connection between the progression of 
both conditions exists. 
 
The present work aims to understand the interaction between vessels and bones in the 
context of rheumatic inflammatory diseases through the study of the effect of inflammation 
on the tissues.  
 
The specific aims of this study were: 
 
I.To evaluate how, in inflammatory rheumatic diseases, the vessels are disturbed, leading 
to vascular alterations and CV disease; 
II.To evaluate how bone metabolism biomarkers are affected by inflammatory rheumatic 
diseases; 
III.To understand the role of inflammation as a common contributor to the interplay 
between bones and vessels, in the context of health and illness. 
 
 
 
 
  
34 
 
 
 
35 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
  
36 
 
  
37 
 
To achieve the first aim, a convenience cohort of patients with SLE and RA women fulfilling the 
ACR classification criteria and without previous CV events were consecutively recruited 
between May 2007 and October 2010. A control group of women without systemic 
inflammatory diseases was also recruited. Demographic data, disease characteristics, current 
medication, and CV risk profile including blood pressure, serum lipids, fasting glycemia, 
smoking habits, and BMI were obtained. Cytokines and soluble vascular biomarkers were 
determined using commercial enzyme-linked immunosorbent assays (ELISA); endothelial 
function was assessed by peripheral artery tonometry (PAT), a noninvasive operator-
independent method that evaluates changes in pulse wave amplitude before and after 
reactive hyperemia; high-definition carotid ultrasonography was assessed for a subgroup of RA 
patients, with cIMT measured in the common carotid artery and the identification of carotid 
atherosclerotic plaques. 
Patients with RA were reassessed after 5 years of follow-up and the incidence of CV events 
identified (acute myocardial infarction, unstable angina and coronary revascularization 
through percutaneous coronary intervention or coronary artery bypass grafting, stroke, 
transient ischemic attack, peripheral artery disease and death due to any of these events.). 
 
For the second aim, SLE patients were studied and serum measurements of erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), lipids (total cholesterol, HDL, LDL and 
tryglicerides), anti-dsDNA and anti-Sm antibodies, and sRANKL and OPG were performed. 
 
For the third aim, ApoE deficient female mice were used, and as a control group we used 
C57BL/6 strain female mice. All groups were fed a high-fat diet (atherogenic diet) and mice 
were euthanized with CO2 at different time-points: 8, 16, 20, 24 and 28 weeks old. Blood (for 
bone markers quantification by ELISA), the aorta (for either lesions quantification with oil red 
O staining or gene expression studies of inflammation and bone proteins), and bones (femurs 
and tibias for three-point bending tests and L3-L4 vertebras for histomorphometry analysis) 
were collected from all mice.  
Furthermore, a sample of bone from the iliac crest and a section of the abdominal aorta artery 
were collected from 45 cadaver donors at the time of organ collection for transplantation, 
between April 2013 and September 2015. In addition, atherosclerotic plaques were collected 
from 139 patients submitted to carotid endarterectomy surgery between May 2012 and May 
2015; all patients performed a DXA and a structured protocol was applied to all patients for 
recording demographic data, CV risk factors, history of previous factures, personal and family 
history of OP, other comorbidities, lifestyle and nutritional habits, and past and current 
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medication. Fasting blood samples were collected from both donors and patients for cytokines 
and bone markers quantification. RNA was extracted from the biological samples for gene 
expression determination of bone remodeling and inflammatory proteins. The atherosclerotic 
plaques were evaluated by histological and immunohistochemical techniques for calcium, 
inflammatory cells and adiponectin content.  
 
Materials and methods are further detailed in the publications inserted in the Results section. 
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The association between vascular and skeletal systems has been investigated over the last few 
years, particularly in the context of rheumatic inflammatory diseases where these systems are 
often altered in the same individual, such as in RA or SLE. In addition, the role of inflammation 
has also been studied in the development and progression of these diseases and of the 
comorbidities affecting the vascular and skeletal systems. The paradox between vascular 
calcification and low bone density has raised the curiosity of researchers, and several studies 
have been developed not only in mice but also in humans. However, the mechanisms 
underlying these processes have yet to be clarified. 
The goal of the present work was to add knowledge to the processes underlying the 
interaction between vessels and bones in the context of rheumatic inflammatory diseases, 
specifically in RA and SLE, through the study of the effect of inflammation on the tissues. 
 
The first part of this thesis focused on the effect of inflammatory rheumatic diseases on the 
vessels, leading to vascular alterations and CV disease. We have assessed the early vascular 
alterations observed in patients with RA and SLE, without previous CV events, through the 
determination of serum levels of vascular biomarkers and the study of endothelial function 
(part I). We found that patients had elevated serum levels of sICAM-1, thrombomodulin (TM) 
and tissue factor (TF) compared to controls. Also, vascular biomarkers correlated with 
inflammatory parameters and were found to be higher in active disease than in quiescent 
disease. Overall, early vascular changes were more pronounced in lupus. In SLE patients we 
found a marked increase in serum sICAM-1 and TM, whereas RA was characterized by elevated 
TF levels. Adhesion molecules might represent a link between inflammation and 
atherosclerosis, since their increased expression on atherosclerotic lesions has been previously 
documented 402,403 and the high serum levels of these molecules, in particular of sICAM-1, 
stand as an independent risk factor for atherosclerosis and a predictor of CV events 404,405. 
Fibrinogen, when binding to ICAM-1, promotes adhesion and transendothelial migration of 
leukocytes, an initial step in vascular inflammation 51. We have found, that not only fibrinogen 
was as an independent predictor of endothelial dysfunction in SLE and RA, but also both 
sICAM-1 and fibrinogen were higher in patients with SLE than in patients with RA. Expression 
of TM, a molecule with anti-coagulant properties, is decreased during the inflammatory 
process and elevated serum levels of this molecule are an indicator of probable endothelial 
injury 406. Together with increased TF, an initiator of the extrinsic coagulation pathway, they 
create an environment favorable to thrombotic complications. We found no differences in 
endothelial function measured by PAT between patients and controls, nor between SLE and 
RA. However, patients with SLE had a higher Alx, which indicates a worse vascular condition. 
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The higher CV risk of lupus patients as compared to RA patients was corroborated by the more 
pronounced early vascular changes and more elevated vascular serum markers. 
 
We have then assessed the incidence of CV events in the RA cohort at 5 years of follow up 
(part II), evaluating the contribution of traditional CV disease risk factors and RA-related 
parameters to future events. Four CV events occurred in this cohort, contributing to an 
incidence rate of 7 per 1000 person-years, which is much higher than what is estimated for the 
general Portuguese population without RA 407,408. We have identified that ESR and sICAM-1 
serum levels were independent predictors of the occurrence of CV events. A pro-inflammatory 
status has been associated with higher CV risk and mortality in RA patients 409, and it has also 
been shown that those with active disease have less stable carotid plaques 410. The presence of 
carotid plaques is a helpful indicator of patients at higher risk of development of CV events. 
Also, the heterogenous type of plaques are more prone to evolve to plaque hemorrhage and 
thrombotic events 411–413. In our study, those patients who suffered a CV event had mainly 
homogeneous plaques at baseline, unlike to what would be expected. However, it would be 
interesting to have a re-evaluation of these patients by carotid ultrasound to understand if 
some changes in the carotid plaques, together with other factors such as traditional CV risk 
factors, sICAM-1 levels and therapy, specifically with corticosteroids, might justify the 
evolution of those plaques to more vulnerable ones, leading to the occurrence of CV events.  
 
We have further evaluated how bone metabolism biomarkers, specifically sRANKL and OPG, 
are affected by inflammatory rheumatic diseases, specifically in SLE patients (part III). We have 
found that OPG serum levels were lower in SLE patients than in controls and were inversely 
associated with anti-dsDNA levels, which in turn were directly related with disease activity 
defined according to SLEDAI-2K. Thus, those patients with a more active disease were more 
exposed to the effect of RANKL/RANK interaction as a consequence of diminished OPG levels. 
We have not found significant differences in serum RANKL levels between SLE patients and 
healthy controls, but the sRANKL/OPG ratio was increased in patients, at the cost of serum 
OPG decreased levels. Additionally, sRANKL/OPG ratio was found to be associated with anti-
Sm antibodies, often present in active SLE 414–416. An increased sRANKL/OPG ratio has been 
associated with bone loss in immune mediated inflammatory diseases 132,417 and it has been 
previously described in RA 418,419. Our findings suggest that SLE per se has an important role in 
accelerating osteoclastogenesis, and consequently bone loss, since the sRANKL/OPG ratio was 
found to be independently associated with anti-Sm levels and was not associated with 
corticosteroids therapy. 
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At last, we aimed to understand the role of inflammation as a common contributor to the 
interplay between bones and vessels. For that we have first used a mouse model of 
atherosclerosis (ApoE-/-) and evaluated both bones and vessels disturbances, as well as tested 
their association with inflammatory markers (part IV). Secondly, using human samples from 
organ donors and from endarterectomized patients with advanced atherosclerosis (part V), we 
have evaluated the role of inflammation in the relationship between bone metabolic 
disturbances, specifically OP, and vascular disease classifiable as atherosclerosis.   
 
We have found that in ApoE-/- mice, comparing to wild type mice, the ratio between bone 
turnover markers CTX-I/P1NP increased as mice got older, as a result from both an increase in 
CTX-I serum levels and a decrease in P1NP serum levels, suggesting an activation of bone 
turnover over time. Also, histomorphometric analysis of these mice bones revealed a decrease 
in bone volume and trabecular thickness and an increase in trabecular separation, which were 
in accordance with an increased bone turnover over time. However, these results did not 
translate in increased bone fragility, as assessed by biomechanical testing. ApoE-/- mice have an 
accelerated progression of atherogenesis when fed a high-fat diet 388,420 and we have subjected 
both the experimental group and the control group to an atherogenic diet from 10 weeks old, 
to minimize the environmental differences between groups. However, there are some studies 
providing evidence that both age 392 and a high-fat diet 393,394 have an effect on ApoE-/- mice 
bone mass, leading to a decrease on bone formation, probably through blocking the 
differentiation of OB progenitor cells 395. Thus, the lack of differences between ApoE-/- mice 
and the control group observed in our work might be justified by the diet. To confirm this 
hypothesis a comparison with animals fed a normal chow diet would be necessary.  
We have further analyzed the expression of inflammation and bone remodeling proteins 
without finding any differences between groups neither over time, nor any relationship 
between the expression of these proteins and bone biomechanical or histomorphometric 
evaluations, reinforcing the idea that other factors, such as altered lipid transport and high-fat 
diet associated with mice aging, might play a more relevant role on atherosclerosis progression 
and bone disturbances than inflammation in this animal model. 
 
In the last part of this project, using deceased donors’ samples, we have found a positive 
correlation in the expression of several genes related to inflammation and bone remodeling 
between bones and vessels. Importantly, this is not a widespread finding, as confirmed by the 
lack of association with adipose tissue samples from the same individuals. Also, we found that 
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bone remodeling proteins were expressed on vessels of individuals without identified CV 
disease. Regarding bone remodeling proteins, we could expect an inverse relationship 
between bones and vessels, since an association between atherosclerotic lesions calcification 
and bone loss had been previously described 257,421,422. However, we have found a direct 
relationship, leading us to hypothesize the existence of different patterns of expression in 
normality and in pathology, in line with the previous described 423 changes in the gene 
expression of calcification regulators in the setting of atherosclerosis progression. No effect of 
age or gender on gene expression pattern were found, pointing to an intrinsic connection 
between bone and vessel disturbances. 
 
We have found that more than 45% of the patients with advanced atherosclerosis had low 
BMD, accordingly to the age range of this population and to previous studies 244,424. In those 
patients with lower BMD, the expression of bone formation genes (CBFA1 and OCL) on carotid 
atheroma plaques was lower, which could indicate a lower tendency to plaque calcification. 
However, no differences were found in the calcium content as determined by Alizarin Red S 
staining between patients with normal or low BMD. On the contrary, previous studies 425–427 
have reported an association between low BMD and vascular calcification, suggesting that the 
analysis of the plaques at different stages of development might influence the genes 
expressed. 
Statins were described as having a positive effect on bone metabolism 428, namely through an 
antiresorptive effect on bone cells, and inhibition of the inflammatory process 429, they have 
been simultaneously associated to an increase in carotid plaques calcification 430 aside to 
plaques regression and composition change 431–434. Accordingly, increased gene expression 
levels of OCL (expressed by differentiated OBs) were found in the plaques of our patients 
under statins therapy. Nevertheless, we found that a high percentage (about 46%) of our 
patients under statins therapy have decreased BMD. 
Lastly, carotid atheroma plaques immunohistochemical analysis revealed that both CD3 
positive cells and CD68 positive cells were highly present in males’ plaques, suggesting that 
plaques are more inflammatory in men than in women, as previously proposed 435,436. Also, 
CD3 positive cells were infrequent in the plaques of patients with low BMD levels, which were 
expected to have echogenic (more calcified) plaques with lower inflammation 437–439, as 
calcification and inflammation are thought to be active at different stages of disease 
progression 440, with inflammation at early phases and calcification predominantly later 
436,441,442. 
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Previous epidemiological studies have shown that CV diseases and osteoporosis are 
responsible for high rates of morbidity and mortality, share common risk factors, and 
are often present in the same individual, with the inflammatory process implicated in 
the pathogenesis of both diseases, particularly in patients with immune mediated 
rheumatic diseases. 
 
In this PhD project we have confirmed the role of inflammation in the pathogenesis of 
atherosclerosis in chronic inflammatory rheumatic diseases. Moreover, baseline levels 
of inflammation and endothelial activation markers contributed significantly to the 
occurrence of CV events over the following 5 years.  We also found differences 
between SLE and RA, with more pronounced early vascular changes in lupus patients.  
We have also described a raised sRANKL/OPG ratio in female SLE patients, suggestive 
of increased osteoclastic stimuli in this group. 
In the ApoE-/- mouse model, the altered lipid transport and a high-fat diet, associated 
with mice aging, may play a more relevant role than inflammation in the development 
of vessels and bone disturbances. 
Additionally, in humans without inflammatory diseases we found a direct correlation 
of the expression of inflammatory and bone remodeling proteins between bones and 
vessels, independently of age and gender.  
 
This work suggests that the association between atherosclerosis and osteoporosis rely on 
an intrinsic connection between the tissues involved and that the contribution of the 
risk factors for the progression of these diseases, namely inflammation, affect more 
pronouncedly patients with immune-mediated rheumatic diseases than healthy 
subjects. It is thus crucial to closely monitor bone quality in CV disease patients, as well 
as control atherosclerosis development in patients with poor bone quality to ensure 
early detection and prevention of the progression of these conditions. This strategy 
should be followed even more tightly in patients with immune mediated rheumatic 
diseases such as RA and SLE. 
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